On July 3, Hengrui Pharma rose 3.2% in regular trading, trading at HKD 60.4/share, with turnover of HKD 51.29 million. The stock was buoyed by a wave of positive catalysts and broad pharmaceutical sector strength.

On the news front, the company received multiple regulatory milestones in quick succession. Its subsidiary's marketing application for recombinant trastuzumab injection was accepted by China's NMPA and granted priority review status. Additionally, SHR-8068 injection combined with adebrelimab and bevacizumab received Phase III clinical trial approval for unresectable hepatocellular carcinoma. The company's self-developed PD-L1 inhibitor adebrelimab also secured approval for a new perioperative indication in non-small cell lung cancer, becoming the first domestically developed PD-L1 inhibitor approved for this indication in China. Meanwhile, the EMA accepted the company's marketing application for revulutamide tablets for prostate cancer, marking its first self-developed innovative drug submitted for EU approval.

Within the Pharmaceuticals sector, stocks rallied broadly. Among individual names, Haixi Pharma up 5.93%, Luye Pharma up 7.53%, Hansoh Pharma up 4.6%, CSPC Pharma up 4.37%, SBP Group up 3.46%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)